Furthermore, the CTLA-4 competitive binding to B7.1 inhibits IL-2 production and proliferation, both of which are essential in down-regulating T cell activity; in turn, this reduces anti-tumor responses and increases cancer susceptibility (5). Here, CTLA4 is linked to cancer.